All In Biotech

Drug Trial Radar · NCT07947121

A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)

A Phase 3 Randomized Open-Label Study to Evaluate the Safety and Efficacy of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Newly Diagnosed Extensive Stage Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Dec 25, 2026

Primary completion

Feb 24, 2031

Study completion Mar 24, 2032

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Nov 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive type of lung cancer. Current treatment options are limited, and response to treatment may not last long. Outcomes are especially poor when the cancer has spread to the brain. This study tests whether a new treatment: risvutatug rezetecan (Ris-Rez) with atezolizumab works better than standard of care treatment. Ris-Rez is designed to deliver cancer-killing medicine directly to cancer cells. Atezolizumab helps the immune system attack cancer cells. Researchers will see if this combination helps people live longer and keeps the cancer from getting worse.

Conditions

  • Lung Neoplasm

Interventions

  • Ris-RezBiological

    Ris-Rez will be administered.

  • AtezolizumabBiological

    Atezolizumab will be administered.

  • EtoposideDrug

    Etoposide will be administered.

  • CarboplatinDrug

    Carboplatin will be administered.

  • LurbinectedinDrug

    Lurbinectedin will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Up to 50 months
  2. Progression-free survival (PFS) by Blinded independent central review (BICR) assessmentTime frame: Up to 50 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.